Research programme: pifithrin compounds - Quark Pharmaceuticals

Drug Profile

Research programme: pifithrin compounds - Quark Pharmaceuticals

Alternative Names: Oncology research programme - Quark; PFT; PFT-X; PFT-β; QG-AGC1; QG-AGC6

Latest Information Update: 31 Aug 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Quark Biotech
  • Developer Quark Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Tumour suppressor protein p53 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alopecia

Most Recent Events

  • 10 Mar 2005 Quark is actively seeking strategic partners for development of its oncology portfolio
  • 31 Jul 2003 Preclinical development for Alopecia (Chemotherapy-induced, Prevention)/Chemoprotection in USA (unspecified route)
  • 31 Jul 2003 Preclinical development for Radiation injuries (Prevention)/Radioprotection in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top